Intuitive Surgical, IncNasdaq: ISRG
Health Care · Health Care Equipment
$458.41
+0.17%
Vol: 1.1M
Research Digest
Friday, May 1, 2026
Intuitive Surgical Q1 2026 EPS beat $1.92 estimates by 30% at $2.50; raised full-year guidance on strong procedure growth
Intuitive reported Q1 2026 EPS of $2.50 (beat estimate of $1.92 by 30%) with $2.77B revenue (+23% YoY). Da Vinci procedures grew ~16% and Ion procedures ~39%. Completed $9.08B share buyback of 29.4M shares. Installed base reached 11,395 systems (+12% YoY). Raised FY2026 guidance to 13.5%-15.5% da Vinci procedure growth. Stock down 3.05% recently on regulatory concerns (FDA safety alerts on stapling devices), but trading near $590 (+40% from Oct 2025 lows).
Previous Market Intelligence
13 daysApr 30Intuitive Surgical Q1 crushes expectations with 23% revenue growth to $2.77B; stock pulled back on FDA stapler alertMixed▶
Intuitive Surgical reported blowout Q1 2026 results with revenue rising 23% year-over-year to $2.77B, well ahead of consensus for $2.62B, and net income of $821.5M (+38% EPS to $2.50). Da Vinci procedures grew 16% and Ion procedures surged 39%; system placements rose to 431 (vs 367 prior year). The company completed its multi-year $9.08B buyback of 29.4M shares, signaling confidence. However, ISRG stock pulled back 3.3% amid renewed attention to a recent FDA early alert involving certain surgical stapler reloads and valuation concerns after the sharp post-earnings jump. Bernstein and RBC maintain Outperform with $750 and $650 price targets.
Apr 29Intuitive Surgical Q1 revenue $2.77B (+23% YoY) and non-GAAP EPS $2.50 (+38%) crush expectationsMixed▶
Intuitive Surgical reported blowout Q1 2026 results with revenue of $2.77B, well ahead of $2.62B consensus and up 23% YoY. Non-GAAP EPS soared 38% YoY to $2.50, crushing $2.11 estimate. Company placed 431 da Vinci systems (vs. 367 prior year), with 232 new da Vinci 5 systems reflecting accelerating adoption. Da Vinci procedures grew ~16% and Ion procedures grew ~39%. Stock down 3.05% on 4/29 amid FDA safety alerts on stapling devices, though recurring revenue streams from services and instruments remain strong. 24/7 Wall St. price target: $615.93, implying 27.5% upside.
Apr 16Intuitive Surgical reaffirms 13-15% da Vinci procedure growth for 2026 with April 21 earnings call as key catalyst; Goldman Sachs lowers PT to $609Mixed▶
Intuitive Surgical reaffirmed double-digit da Vinci procedure growth guidance of 13-15% for 2026, supporting the long-term growth narrative despite valuation pressures. Q4 2025 EPS of $2.53 beat consensus of $2.27, with 2026 consensus EPS at $6.43 (+18.66% growth). Goldman Sachs maintained Buy rating but lowered price target from $714 to $609 on April 9. Evercore ISI Group lowered its target from $550 to $480 on April 6. Despite valuation headwinds affecting premium healthcare names, 16 analysts maintain Buy ratings with a $607 consensus price target, implying 34.7% upside.
Apr 14Intuitive Surgical down 19.5% YTD but Goldman Sachs reiterates Buy; 13-15% procedure growth expectedMixed▶
Down 19.5% YTD. Goldman Sachs maintains Buy. BTIG Buy $616 PT. Integrating AI into da Vinci systems. 13-15% procedure growth expected.
Apr 13Da Vinci 5 regulatory approvals expanding; Q1 earnings April 21; cyberattack containedPositive▶
ISRG earnings report April 21 (est. $2.08 EPS, +14.92% YoY; $2.61B revenue, +15.75% YoY). Da Vinci 5 cleared by FDA for cardiac procedures, approved in Europe/Japan. Reported phishing attack on internal systems; da Vinci/Ion robots unaffected. Stock $452.78 (YTD -19.5%). Analyst consensus Buy with $606.76 avg target (+34.65% upside).
Apr 10Intuitive Surgical trades near $453; AI robotics focus drives analyst enthusiasm; earnings April 28.Positive▶
Intuitive Surgical trading around $452.95 with analyst consensus Strong Buy rating and median price target of $615.50 implying 36% upside. Strong Q4 2025 results with $2.87B revenue and $2.53 EPS. Mairs & Power Growth Fund added company to portfolio. Earnings scheduled for April 28, 2026.
Apr 9Intuitive Surgical Price Target Cut to $480; AI Integration in FocusNeutral▶
Evercore ISI lowered Intuitive Surgical price target to $480 from $550, citing valuation concerns amid AI integration into Da Vinci robotic surgery systems. Company scheduled to report Q1 2026 earnings April 21. Analysts expect double-digit EPS growth. Consensus analyst view "Moderate Buy" with 35% upside implied from $611.77 avg price target.
Apr 8Evercore ISI cuts ISRG price target to $480; phishing attack but da Vinci unaffected.Neutral▶
Intuitive Surgical at $479.71. Evercore ISI lowered target to $480 from $550. Company saw phishing attack but da Vinci/Ion systems unaffected. Q1 2026 earnings April 21. Despite 20% YTD decline, 3-5 year returns strong at 72-76%. 19 Strong Buy / 2 Moderate Buy. Average target $619.85.
Apr 7Intuitive Surgical faces headwinds with phishing incident and slower growth guidance despite da Vinci 5 approvals and fund inflows.Neutral▶
Intuitive Surgical stock down 20.2% over 90 days to $452.07 despite strong 3-year and 5-year returns of 76% and 72.9% respectively. Company experienced phishing attack accessing internal IT applications (da Vinci systems unaffected) and issued Q1 earnings April 21 with guidance of 13-15% 2026 da Vinci procedure growth vs. 18% in 2025. Mairs & Power Growth Fund added to portfolio highlighting da Vinci installed base and recurring consumables revenue. Analysts expect 14.3% EPS growth to $8.25 for fiscal 2026. Average analyst target $619.85 implies 37% upside despite recent challenges.
Apr 6Intuitive Surgical Q4 revenue $2.87B (+18.8% YoY); 2026 guidance reset; phishing incident disclosed.Neutral▶
ISRG Q4 2025 revenue $2.87B (+18.8% YoY); 3.1M da Vinci procedures performed in 2025. 2026 guidance: 13-15% procedure growth (down from 18%). Completed European distribution acquisition. Disclosed phishing incident exposing internal/customer data. Stock down 2.67% pre-market April 3.
Apr 3Intuitive Surgical beats Q4 earnings but stock pulled back sharply after FDA flags safety issues with curved-tip staplers.Negative▶
Intuitive Surgical beat Wall Street estimates in Q4 2025 with EPS of $2.53 (vs. $2.27 consensus) and revenue of $2.87B. Da Vinci procedures grew approximately 18% and Ion procedures grew 51%. On March 30, the stock declined sharply following FDA news about curved-tip stapler safety issues, injuries, and one fatality. The company expects da Vinci procedures to grow 13-15% in 2026. Analyst consensus remains Buy with $611 price target.
Apr 1Intuitive Surgical stock declined 5% after FDA flagged curved-tip stapler safety issues requiring recall; Q1 earnings report due April 21.Negative▶
Intuitive Surgical faces regulatory headwinds after FDA stapler recall concerns triggered recent stock decline. Company reported strong Q4 2025 results with $2.87 billion revenue and 18.8% YoY growth, beating EPS estimates with $2.53 vs. $2.27 expected. Company expects 2026 worldwide da Vinci procedure growth of 13-15% and non-GAAP gross margin of 67-68%. Q1 2026 earnings report scheduled for April 21. Insider selling activity noted throughout March.
Mar 31Intuitive Surgical declines on FDA safety alert and cybersecurity breach; core robotic systems remain operational.Negative▶
Intuitive faced FDA safety alert on curved-tip staplers, stock down 3.09%. Cybersecurity incident from phishing did not impact da Vinci or Ion. European expansion in Italy, Spain, Portugal, Malta, San Marino. Q4 2025 procedures up 17% YoY.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
| EWEDWARDS | $84.28 | +0.93% | +2.9% | 24.8x | 0.94 | $48.1B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.